Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s draft guidance on presenting product information on social media platforms with character space limitations includes an equation for sending a tweet.


Related Content

Gottlieb's Tweets: Skirting The Rules Or Advancing Policy?
Twitter Promo Study Gets Tweaks, But FDA Rejects Many Industry Suggestions
Rx Mobile Devices Promos: Benefits Often More Prominent Than Risks
Regulatory Twitter Goes '#Rogue' With AltFDA
Regulatory Twitter Goes '#Rogue' With AltFDA
Twitter Rx Drug Promos: FDA Studies Best Way To Convey Risk Info
DTC Safety Messages Could Vary By Platform As FDA Considers Screen Size
OMG! Kim Kardashian Social Media Post For Morning Sickness Drug Draws FDA Warning
FDA’s Social Media Guidance Gives Firms A Pass On User-Generated Content
Who's Liable For Online Content? Pharma, Marketers Disagree (Slightly)





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts